Viatris Inc. (NASDAQ:VTRS) J.P. Morgan 42nd Annual Healthcare Conference January 10, 2024 1:30 PM ET Company Participants Scott A. Smith - CEO Rajiv Malik - President Sanjeev Narula - CFO Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good morning, everybody. I'm Chris Schott at J.P. Morgan. And it's my pleasure to be hosting a fireside chat today with Viatris. From the company, we're going to have a quick presentation from CEO, Scott Smith and we're going to open up to a Q&A session w ...

Amarin Corporation plc (NASDAQ:AMRN) 42nd Annual J.P. Morgan Healthcare Conference January 10, 2024 4:30 PM ET Company Participants Pat Holt - President & CEO Conference Call Participants Jess Fye - JPMorgan Jess Fye Great. Good afternoon, everyone. Welcome. My name is Jess Fye. I'm a Senior Biotech Analyst at JPMorgan, and we're continuing the 42nd Annual Healthcare Conference today with Amarin. I'm joined up here by the company's President and CEO, Pat Holt. He's going to give a presentation on the busine ...

Summary of Intuitive Surgical, Inc. Conference Call Company Overview - **Company**: Intuitive Surgical, Inc. (NASDAQ: ISRG) - **Event**: JPMorgan Healthcare Conference Call - **Date**: January 10, 2024 Key Points Industry and Market Dynamics - The company focuses on minimally invasive care and acute interventions, emphasizing the need for advanced technologies to improve healthcare outcomes [2][3] - The total experience on da Vinci platforms has surpassed 14 million procedures, with over 2.2 million procedures performed in the last year [3][4] - The installed base of systems has grown to over 9,100, with significant placements across various platforms [4] Financial Performance - The company reported a 22% growth in procedures for the year, with a projected growth rate of 13% to 16% for 2024 [10][46] - Revenue growth is slower than procedure growth due to a higher mix of risk-sharing arrangements and leasing in the capital portfolio [12][13] - The installed base grew by 14%, indicating increased utilization of systems [11] Challenges and Risks - Environmental uncertainties in China, including regulatory pressures and pricing regulations, have impacted business performance [5] - The rise of GLP-1 medications has led to a deceleration in bariatric surgery growth, which is expected to continue [6][48] - Manufacturing constraints, particularly in the flexible bronchoscopy space, have limited system installations [7][8] Growth Opportunities - The company sees a potential market of approximately 7 million patients annually, with aspirations to grow this to 21 million through innovation [14][15] - The Ion system for flexible bronchoscopy is gaining traction, with significant growth in procedures [16][17] - The company is focused on expanding its platforms and indications, particularly in international markets [39] Technological Advancements - Intuitive Surgical is investing in AI and machine learning to enhance surgical outcomes and operational efficiency [24][26] - The company is developing tools for preoperative planning, intraoperative guidance, and postoperative analytics [28][30] - The integration of telemedicine and teleproctoring capabilities is being explored to enhance surgical support [33] Customer Engagement and Satisfaction - The company measures customer satisfaction through Net Promoter Scores, achieving an 80% score in the U.S. [38] - The focus is on aligning with customer needs and demonstrating the value of their products through data-driven outcomes [61][62] Future Outlook - The company plans to focus on innovation, quality improvement, and optimizing manufacturing processes in 2024 [39][55] - There is an emphasis on understanding the impact of AI and big data on the surgical robotics field over the next decade [64] Additional Insights - The company is cautious about the impact of economic conditions on procedure growth, particularly in relation to patient backlogs and market dynamics in China [47][48] - The competitive landscape is influenced by disease state-level competition, with a focus on delivering better patient outcomes and experiences [60][61] This summary encapsulates the key insights from the conference call, highlighting the company's performance, challenges, growth opportunities, and strategic focus areas for the future.

AbbVie Inc. (NYSE:ABBV) J.P. Morgan 42nd Annual Healthcare Conference January 10, 2024 11:15 AM ET Company Participants Rob Michael - President and Chief Operating Officer Jeff Stewart - Chief Commercial Officer Roopal Thakkar - Chief Medical Officer Conference Call Participants Chris Schott - J.P.Morgan Chris Schott Good morning, everybody. I'm Chris Schott at J.P.Morgan, and it's my pleasure to be hosting a fireside chat today with AbbVie. From the company, we have Rob Michael, President and Chief Operati ...

Bruker Corporation (NASDAQ:BRKR) 42nd Annual J.P. Morgan Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Frank Laukien - President and Chief Executive Officer Gerald Herman - Executive Vice President and Chief Financial Officer Mark Munch - President, Bruker Nano Group and Corporate Executive Vice President Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal This is Rachel Vatnsdal from the life science tools and diagnostics team at JPMorgan. Pleased to introduce ...

Editas Medicine, Inc. (NASDAQ:EDIT) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 7:30 PM ET Company Participants Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Conference Call Participants Brian Cheng - J.P. Morgan Brian Cheng Good afternoon. Thanks for joining us for another session at the 42nd J.P. Morgan Healthcare Conference. I'm Brian Cheng, I'm one of the Senior Biotech Analysts here at the firm. I'm joined by my associate, Sean Kim, who is also in the audience. On stage, ...

Summary of CRISPR Therapeutics AG Conference Call Company Overview - **Company**: CRISPR Therapeutics AG (NASDAQ: CRSP) - **Event**: 42nd Annual J.P. Morgan Healthcare Conference - **Date**: January 9, 2024 - **CEO**: Dr. Sam Kulkarni Key Points Industry and Company Background - CRISPR Therapeutics is at the forefront of gene editing technology, specifically CRISPR Cas9, which has been revolutionary in biomedicine [2][6] - The company has diversified its portfolio into oncology, cardiovascular medicine, and diabetes, with several data catalysts expected in 2024 [3][4] Product Development and Pipeline - **CASGEVY**: The approval of CASGEVY for sickle cell disease and thalassemia is highlighted as a historic achievement, with a focus on expanding its addressable population through a targeted conditioning agent [6][7] - **In Vivo Approaches**: The company is advancing in vivo editing of hematopoietic stem cells (HSCs) and has received a $15 million Gates grant to support this work [8] - **2024 Priorities**: The company aims to develop three additional franchises: immuno-oncology, cardiovascular, and type 1 diabetes, with multiple clinical trials ongoing [9][10] Manufacturing and Operational Efficiency - CRISPR Therapeutics has established its own state-of-the-art manufacturing facility, which won the Facility of the Year Award, allowing for scalable production [5][19] - The company reports a significant reduction in cost of goods sold (COGS), down 4x from CTX110 to CTX112, enhancing its ability to bring therapies to market efficiently [19][20] Competitive Landscape and Future Outlook - The company is optimistic about the potential of allogeneic CAR-T therapies, particularly in autoimmune diseases, and is moving forward with urgency in this area [12][14] - The potential for solid tumors is emphasized, with CTX131 showing promising results in renal cell carcinoma [16][18] - The company is exploring partnerships to expand its capabilities and manage its extensive pipeline, with increasing interest from big pharma in cell and gene therapies [48] Financial Health and Growth Strategy - CRISPR Therapeutics has a strong balance sheet to support its growth initiatives, with five assets in the clinic and seven different clinical readouts expected in 2024 [29][28] - The company is focused on maintaining flexibility in its manufacturing strategy, balancing in-house capabilities with outsourcing for efficiency [50][51] Conclusion - CRISPR Therapeutics is positioned for significant growth in 2024, with a robust pipeline and innovative gene editing technologies that could transform treatment paradigms across multiple diseases [30][29]

Organon & Co. (NYSE:OGN) JPMorgan 42nd Annual Healthcare Conference Call January 9, 2024 4:30 PM ET Company Participants Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Conference Call Participants Christopher Schott - JPMorgan Christopher Schott Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it is my pleasure to be hosting this fireside chat with the Organon management today. From the company, we have CEO, Kevin Ali; as well as CFO, Matt Walsh. Kevin and Matt, Happy N ...

Eli Lilly and Company (NYSE:LLY) JPMorgan 42nd Annual Healthcare Conference January 9, 2024 4:15 PM ET CorporateParticipants Dave Ricks - Chairman and Chief Executive Officer ConferenceCall Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat this afternoon with Eli Lilly. Lilly has obviously had a tremendous few years here and really looking forward to our discussion with Dave Ricks, company's Chairman ...

Teladoc Health, Inc. (NYSE:TDOC) 42nd Annual JPMorgan Healthcare Conference January 9, 2024 4:30 PM ET Company Participants Jason Gorevic - CEO Conference Call Participants Lisa Gill - JPMorgan Lisa Gill Good afternoon. My name is Lisa Gill, and I am the Head of Healthcare Services at JPMorgan. With me this afternoon, I have Teladoc Health. Presenting for Teladoc is CEO, Jason Gorevic. When Jason has done with his presentation, he'll join me over here, and we'll have a little fireside chat. So with that, ...